Status:

COMPLETED

Stereotactic Radiosurgery in Treating Patients With Spinal Metastases

Lead Sponsor:

Boston Medical Center

Collaborating Sponsors:

United States Department of Defense

Conditions:

Metastatic Cancer

Eligibility:

All Genders

18+ years

Phase:

PHASE1

Brief Summary

RATIONALE: Stereotactic radiosurgery can send x-rays directly to the tumor and cause less damage to normal tissue. It may also help patients with spinal metastases live more comfortably. PURPOSE: Thi...

Detailed Description

OBJECTIVES: * To implement CyberKnife® technology for improving palliation in patients with spinal metastases. * To determine the maximum tolerated dose of CyberKnife® hypofractionated stereotactic r...

Eligibility Criteria

Inclusion

  • DISEASE CHARACTERISTICS:
  • Histologically confirmed metastatic spinal tumor
  • Localized spinal metastasis, defined as one of the following:
  • Solitary spinal metastasis
  • Two contiguous spinal levels
  • No more than 2 adjacent spinal levels involved by a single tumor
  • Involvement of ≤ 3 separate sites (e.g., C5, T5, and T12)
  • Tumor size ≤ 5 cm
  • PATIENT CHARACTERISTICS:
  • Karnofsky performance status 60-100%
  • Life expectancy ≥ 6 months
  • Negative pregnancy test
  • Fertile patients must use effective contraception
  • Must be ambulatory

Exclusion

  • Not pregnant or nursing
  • No spinal instability
  • No rapid neurological decline
  • No bony retropulsions causing neurological abnormalities
  • No total paraplegia for \> 48 hours
  • No psychological issues that would preclude completion of study treatment
  • PRIOR CONCURRENT THERAPY:
  • See Disease Characteristics
  • No prior treatment for spinal tumor that would result in potential overlap of radiotherapy fields
  • No treatment that is expected to exceed spinal cord tolerance or other regional normal tissue tolerance
  • No tumors that are exquisitely radiosensitive and controlled with conventional radiotherapy (e.g., lymphoma, leukemia, multiple myeloma, or germ cell tumors)

Key Trial Info

Start Date :

January 1 2009

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

June 1 2017

Estimated Enrollment :

18 Patients enrolled

Trial Details

Trial ID

NCT00853528

Start Date

January 1 2009

End Date

June 1 2017

Last Update

July 19 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

Boston University Cancer Research Center

Boston, Massachusetts, United States, 02118